Halozyme Therapeutics announced it expects zero to minimal impact on its royalty revenues from the new Medicare Drug Price Negotiation Program finalized by the U.S. Centers for Medicare & Medicaid Services. The company’s analysis indicates that protections for orphan drugs and considerations for biosimilar entries will shield its revenues through at least 2035. Halozyme also anticipates no disruption to its ability to form new partnerships using its ENHANZE® drug delivery technology, which is widely licensed to major pharmaceutical companies. This outlook supports the company’s ongoing efforts to improve patient treatment experiences and maintain competitive advantages in drug delivery solutions.
Halozyme Therapeutics holds a market cap of $13.95 billion and an enterprise value of $15.86 billion on Pluang as of Nov 06, 2026 22:21 WIB. Despite the company's positive outlook on royalty revenues amid new Medicare pricing rules, its stock price has dropped 13.46% in the last day, with a trading volume of 2,863,794 shares. The typical hold time for HALO on Pluang is 3 days, indicating active trading interest around this health sector stock.
The FDA granted accelerated approval to Johnson & Johnson's RYBREVANT FASPRO, a dual-targeted therapy for adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who have progressed after platinum-based chemotherapy and anti...
Halozyme Therapeutics reported a 39% year-over-year revenue increase to $493 million in Q3 2026, driven by a 44% rise in royalty revenue to $341 million. The company expanded its ENHANZE® collaboration agreements and advanced three programs into Phas...
